Table 3.
Genotypic distribution of TLR3 gene polymorphisms when all HCV-infected patients were compared to healthy control group.
| SNPs | Genotype/allele distribution | Healthy controls | HCV patients | OR (95% CI) | χ 2 | p value |
|---|---|---|---|---|---|---|
| n = 599 | n = 563 | |||||
| rs5743311 | AA | 1 (0.17%) | 0 (0%) | 0.360 (0.015–8.846) | 0.93 | 0.336 |
| AG | 10 (1.67%) | 18 (3.2%) | 1.942 (0.889–4.244) | 2.87 | 0.091 | |
| GG | 588 (98.16%) | 545 (96.8%) | Ref | |||
| A | 12 (1%) | 18 (1.6%) | 1.606 (0.770–3.348) | 1.62 | 0.203 | |
| G | 1186 (99%) | 1108 (98.4%) | ||||
| AA+AG.VS.GG | 1.765 (0.826–3.772) | 2.21 | 0.137 | |||
| AA.VS.AG+GG | 2.825 (0.115–69.479) | 0.94 | 0.332 | |||
|
| ||||||
| rs5743312 | TT | 18 (3.01%) | 16 (2.84%) | 0.959 (0.482–1.905) | 0.01 | 0.903 |
| CT | 141 (23.54%) | 139 (24.69%) | 1.063 (0.811–1.393) | 0.2 | 0.657 | |
| CC | 440 (73.46%) | 408 (72.47%) | Ref | |||
| T | 177 (14.77%) | 171 (15.19%) | 1.033 (0.822–1.297) | 0.08 | 0.781 | |
| C | 1021 (85.23%) | 955 (84.81%) | ||||
| TT+CT.VS.CC | 1.051 (0.811–1.362) | 0.14 | 0.705 | |||
| TT.VS.CT+CC | 1.059 (0.535–2.098) | 0.03 | 0.869 | |||
|
| ||||||
| rs1879026 | TT | 23 (3.84%) | 15 (2.66%) | 0.701 (0.361–1.363) | 1.11 | 0.292 |
| GT | 160 (26.71%) | 161 (28.6%) | 1.082 (0.835–1.401) | 0.35 | 0.552 | |
| GG | 416 (69.45%) | 387 (68.74%) | Ref | |||
| T | 206 (17.2%) | 191 (16.96%) | 0.984 (0.792–1.221) | 0.02 | 0.882 | |
| G | 992 (82.8%) | 935 (83.04%) | ||||
| TT+GT.VS.GG | 1.034 (0.806–1.326) | 0.07 | 0.793 | |||
| TT.VS.GT+GG | 1.459 (0.753–2.825) | 1.27 | 0.2602 | |||
|
| ||||||
| rs5743313 | TT | 42 (7.01%) | 37 (6.57%) | 0.952 (0.595–1.524) | 0.04 | 0.838 |
| CT | 250 (41.74%) | 242 (42.98%) | 1.046 (0.824–1.329) | 0.14 | 0.71 | |
| CC | 307 (51.25%) | 284 (50.44%) | Ref | |||
| T | 334 (27.88%) | 316 (28.06%) | 1.009 (0.842–1.210) | 0.01 | 0.921 | |
| C | 864 (72.12%) | 810 (71.94%) | ||||
| TT+CT.VS.CC | 1.033 (0.821–1.300) | 0.08 | 0.783 | |||
| TT.VS.CT+CC | 1.072 (0.678–1.694) | 0.09 | 0.766 | |||
|
| ||||||
| rs5743314 | CC | 44 (7.35%) | 37 (6.57%) | 0.897 (0.563–1.429) | 0.21 | 0.646 |
| GC | 249 (41.57%) | 239 (42.45%) | 1.023 (0.805–1.301) | 0.04 | 0.8501 | |
| GG | 306 (51.09%) | 287 (50.98%) | Ref | |||
| C | 337 (28.13%) | 313 (27.8%) | 0.984 (0.821–1.179) | 0.03 | 0.858 | |
| G | 861 (71.87%) | 813 (72.2%) | ||||
| CC+GC.VS.GG | 1.004 (0.798–1.264) | 0 | 0.971 | |||
| CC.VS.GC+GG | 1.127 (0.716–1.773) | 0.27 | 0.605 | |||
|
| ||||||
| rs5743315 | AA | 9 (1.5%) | 3 (0.53%) | 0.352 (0.095–1.309) | 2.65 | 0.104 |
| AC | 123 (20.53%) | 118 (20.96%) | 1.014 (0.763–1.347) | 0.01 | 0.926 | |
| CC | 467 (77.96%) | 442 (78.51%) | Ref | |||
| A | 141 (11.77%) | 124 (11.01%) | 0.928 (0.718–1.199) | 0.33 | 0.566 | |
| C | 1057 (88.23%) | 1002 (88.99%) | ||||
| AA+AC.VS.CC | 0.969 (0.733–1.280) | 0.05 | 0.822 | |||
| AA.VS.AC+CC | 2.847 (0.767–10.572) | 2.67 | 0.102 | |||
|
| ||||||
| rs111611328 | CC | 3 (0.5%) | 1 (0.18%) | 0.353 (0.037–3.404) | 0.89 | 0.346 |
| GC | 6 (1%) | 5 (0.89%) | 0.883 (0.268–2.909) | 0.04 | 0.837 | |
| GG | 590 (98.5%) | 557 (98.93%) | Ref | |||
| C | 12 (1%) | 7 (0.62%) | 0.618 (0.243–1.576) | 1.03 | 0.309 | |
| G | 1186 (99%) | 1119 (99.38%) | ||||
| CC+GC.VS.GG | 0.706 (0.250–1.997) | 0.43 | 0.509 | |||
| CC.VS.GC+GG | 2.829 (0.293–27.275) | 0.88 | 0.347 | |||
|
| ||||||
| rs78726532 | GG | 12 (2%) | 3 (0.53%) | 0.264 (0.074–0.942) | 4.84 | 0.027 |
| AG | 120 (20.03%) | 118 (20.96%) | 1.039 (0.781–1.382) | 0.07 | 0.793 | |
| AA | 467 (77.96%) | 442 (78.51%) | Ref | |||
| G | 144 (12.02%) | 124 (11.01%) | 0.906 (0.702–1.169) | 0.58 | 0.447 | |
| A | 1054 (87.98%) | 1002 (88.99%) | ||||
| GG+AG.VS.AA | 0.969 (0.733–1.280) | 0.05 | 0.822 | |||
| GG.VS.AG+AA | 3.816 (1.071–13.594) | 4.92 | 0.026 | |||
Note: risk alleles are marked in bold letters.